{"title":"Loss of hepatic alpha-1b adrenoceptor exacerbates inflammation and stellate cell activation in diet-induced MASLD.","authors":"Bernie Efole, Sarra Beji, Mathilde Mouchiroud, Yves Gélinas, Coraline Canivet, Jocelyn Trottier, Cindy Serdjebi, Joel K Elmquist, Jessica Deslauriers, Olivier Barbier, Alexandre Caron","doi":"10.1152/ajpgi.00143.2025","DOIUrl":null,"url":null,"abstract":"<p><p>The brain regulates liver metabolism through neuroendocrine and autonomic pathways, which can be disrupted in metabolic dysfunction-associated steatotic liver disease (MASLD). While autonomic dysfunction, including liver neuropathy, has been reported in MASLD, the role of hepatic sympathetic signaling in disease progression remains unclear. Recent studies show that liver innervation is predominantly of sympathetic nature, suggesting that adrenergic receptors in hepatocytes may influence the pathogenesis of MASLD. We previously identified adrenoceptor alpha-1b (ADRA1B) as the dominant hepatic adrenergic receptor. Here we hypothesized that ADRA1B plays a protective role in MASLD progression. To test this, we generated hepatocyte-specific <i>Adra1b</i> knockout mice (<i>Adra1b</i><sup>LKO</sup>) and induced MASLD with the GAN diet for up to 32 weeks. Liver pathology was quantified by automated image analysis (MorphoQuant), and metabolic phenotyping included glucose tolerance, insulin sensitivity, bile acid composition. Hepatocyte-specific <i>Adra1b</i> deletion did not affect body weight, hepatic lipid accumulation, glucose tolerance, or insulin sensitivity. However, <i>Adra1b</i><sup>LKO</sup> mice exhibited significantly increased hepatic inflammation compared to wild-type controls. These changes were associated with higher hepatic expression of <i>tumor necrosis factor</i> (<i>Tnf</i>) and <i>interleukin-1b</i> (<i>Il1b</i>), as well as an increase in monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6). We also observed elevated transforming growth factor beta (TGF-β) and α-smooth muscle actin (<i>Acta2</i>) expression, suggesting activation of hepatic stellate cells. Additionally, <i>Adra1b</i><sup>LKO</sup> mice displayed higher circulating bilirubin levels, with no significant alterations in albumin and bile acid pool composition. These findings reveal a previously unrecognized role for hepatic ADRA1B in restraining inflammatory responses in MASLD. Loss of <i>Adra1b</i> signaling promotes hepatic inflammation, highlighting a neuroimmune mechanism that may be targeted to prevent disease progression.</p>","PeriodicalId":7725,"journal":{"name":"American journal of physiology. Gastrointestinal and liver physiology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of physiology. Gastrointestinal and liver physiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1152/ajpgi.00143.2025","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The brain regulates liver metabolism through neuroendocrine and autonomic pathways, which can be disrupted in metabolic dysfunction-associated steatotic liver disease (MASLD). While autonomic dysfunction, including liver neuropathy, has been reported in MASLD, the role of hepatic sympathetic signaling in disease progression remains unclear. Recent studies show that liver innervation is predominantly of sympathetic nature, suggesting that adrenergic receptors in hepatocytes may influence the pathogenesis of MASLD. We previously identified adrenoceptor alpha-1b (ADRA1B) as the dominant hepatic adrenergic receptor. Here we hypothesized that ADRA1B plays a protective role in MASLD progression. To test this, we generated hepatocyte-specific Adra1b knockout mice (Adra1bLKO) and induced MASLD with the GAN diet for up to 32 weeks. Liver pathology was quantified by automated image analysis (MorphoQuant), and metabolic phenotyping included glucose tolerance, insulin sensitivity, bile acid composition. Hepatocyte-specific Adra1b deletion did not affect body weight, hepatic lipid accumulation, glucose tolerance, or insulin sensitivity. However, Adra1bLKO mice exhibited significantly increased hepatic inflammation compared to wild-type controls. These changes were associated with higher hepatic expression of tumor necrosis factor (Tnf) and interleukin-1b (Il1b), as well as an increase in monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6). We also observed elevated transforming growth factor beta (TGF-β) and α-smooth muscle actin (Acta2) expression, suggesting activation of hepatic stellate cells. Additionally, Adra1bLKO mice displayed higher circulating bilirubin levels, with no significant alterations in albumin and bile acid pool composition. These findings reveal a previously unrecognized role for hepatic ADRA1B in restraining inflammatory responses in MASLD. Loss of Adra1b signaling promotes hepatic inflammation, highlighting a neuroimmune mechanism that may be targeted to prevent disease progression.
期刊介绍:
The American Journal of Physiology-Gastrointestinal and Liver Physiology publishes original articles pertaining to all aspects of research involving normal or abnormal function of the gastrointestinal tract, hepatobiliary system, and pancreas. Authors are encouraged to submit manuscripts dealing with growth and development, digestion, secretion, absorption, metabolism, and motility relative to these organs, as well as research reports dealing with immune and inflammatory processes and with neural, endocrine, and circulatory control mechanisms that affect these organs.